ADJUVANTS HUMAN APPLICATIONS

Brand Owner (click to sort) Address Description
ADJU-PHOS CRODA INTERNATIONAL PLC Cowick Hall, Snaith Goole East Yorkshire DN149AA United Kingdom Adjuvants for human applications for use in vaccines and blood fractionation; veterinary preparations for use in vaccines;ADJUVANTS-PHOS;Adjuvants for use in experimental immunology;
NANOQUIL CRODA INTERNATIONAL PLC Cowick Hall, Snaith Goole East Yorkshire DN149AA United Kingdom Adjuvants for human applications for use in vaccines; vaccine adjuvants; adjuvants for medical purposes; veterinary preparations for use in vaccines; pharmaceutical preparations for use in immune system diseases and disorders and for stimulating the response of the immune system;Adjuvants for use in the manufacture of pharmaceuticals and experimental immunology pharmaceuticals and veterinary preparations; adjuvants for use in the manufacture of pharmaceutical and veterinary drug candidate preparations;
NANOQUIL CRODA INTERNATIONAL PLC Cowick Hall, Snaith Goole East Yorkshire DN149AA United Kingdom Adjuvants for human applications for use in vaccines; vaccine adjuvants; adjuvants for medical purposes; veterinary preparations for use in vaccines; pharmaceutical preparations for use in immune system diseases and disorders and for stimulating the response of the immune system;Adjuvants for use in the manufacture of pharmaceuticals and experimental immunology pharmaceuticals and veterinary preparations; adjuvants for use in the manufacture of pharmaceutical and veterinary drug candidate preparations;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.